Article

Blue blocking IOLs are not the best option

Ultraviolet (UV) and violet blocking intraocular lenses (IOLs) can provide protection from radiation and offer good quality of vision, however, blocking blue light can actually cause a loss in quality of vision.

Ultraviolet (UV) and violet blocking intraocular lenses (IOLs) can provide protection from radiation and offer good quality of vision, however, blocking blue light can actually cause a loss in quality of vision, according to Alessandro Franchini and Eleonora Vaccari from the University of Florence, Italy.

The study, which aimed to compare three different IOL filters, was conducted using a dedicated software and a pseudophakic eye model. The eye CIE day and night curves were computed through three different filters: the first blocks UV wavelights from 300 to 400 nm, the second blocks UV and violet (400 to 440 nm) wavelights (UVV) and the third blocks UV, violet and 50% of blue light at 450 nm and 25% at 480 nm (UVVB).

The investigators found that there were negligible differences between the three filters in day curves. In scotopic conditions, the UV filter guaranteed an integral of efficiency of 23.7 (100%), the UVV filter of 23.31 (97%) and the UVVB of 21.49 (90%).

According to Dr Franchini and Dr Vaccari, there is no proof that blocking blue light can guarantee further retinal protection and, given that it can actually cause a reduction in quality of vision, the authors conclude that UV and violet light blocking IOLs offer the best solution.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.